Table 2

Univariate Cox regression analysis of variables associated with death in all patients after listing for liver transplantation

 Cox regression analysis
Outcome death (censored at transplant)
Competing risk Cox regression analysis
Outcome death
HR95% CIp ValueHR95% CIp Value
Age (years)0.990.97 to 1.020.5431.010.99 to 1.040.317
Female gender0.840.53 to 1.330.4630.940.60 to 1.480.787
Blood group
 A1.250.78 to 1.991.110.70 to 1.76
 B/AB0.860.42 to 1.750.4910.870.43 to 1.770.769
Body mass index >30 (kg/m2)1.250.78 to 2.000.3471.180.74 to 1.870.493
Hepatocellular carcinoma0.660.28 to 1.510.3220.520.23 to 1.160.111
eGFR <60 mL/min/1.73 m21.070.66 to 1.750.7771.310.81 to 2.130.276
Hyponatraemia2.791.78 to 4.36<0.0011.781.16 to 2.740.009
MELD score1.141.09 to 1.19<0.0011.030.99 to 1.070.202
UKELD score1.141.09 to 1.18<0.0011.051.01 to 1.100.029
Previous variceal haemorrhage0.610.37 to 0.990.0470.720.45 to 1.170.190
Refractory ascites1.420.91 to 2.220.1191.260.82 to 1.960.292
Prophylactic antibiotics0.710.40 to 1.270.2450.560.32 to 0.990.044
NSBB0.520.34 to 0.820.0040.680.44 to 1.040.076
  • p Value in bold indicates statistical significance.

  • Reference group (relative risk 1.00): male gender, blood group O, body mass index ≤30, no hepatocellular carcinoma, eGFR ≥60 mL/min/L.73 m2, no hyponatraemia, no previous variceal haemorrhage, no refractory ascites, no prophylactic antibiotics and no NSBB.

  • eGFR, estimated glomerular filtration rate; MELD, model for end-stage liver disease; NSBB, non-selective β-blockers; UKELD, UK Score for Patients with End-Stage Liver Disease.